60 related articles for article (PubMed ID: 1700002)
21. Characterization of HIV-1 neutralization escape mutants.
McKeating JA; Gow J; Goudsmit J; Pearl LH; Mulder C; Weiss RA
AIDS; 1989 Dec; 3(12):777-84. PubMed ID: 2483618
[TBL] [Abstract][Full Text] [Related]
22. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution.
Wolfs TF; Zwart G; Bakker M; Valk M; Kuiken CL; Goudsmit J
Virology; 1991 Nov; 185(1):195-205. PubMed ID: 1656585
[TBL] [Abstract][Full Text] [Related]
23. Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development.
Goudsmit J; Back NK; Nara PL
FASEB J; 1991 Jul; 5(10):2427-36. PubMed ID: 2065891
[TBL] [Abstract][Full Text] [Related]
24. Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1.
Yuste E; López-Galíndez C; Domingo E
J Virol; 2000 Oct; 74(20):9546-52. PubMed ID: 11000225
[TBL] [Abstract][Full Text] [Related]
25. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
26. Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration.
Nishitsuji H; Kohara M; Kannagi M; Masuda T
J Virol; 2006 Aug; 80(15):7658-66. PubMed ID: 16840344
[TBL] [Abstract][Full Text] [Related]
27. The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope.
Harada S
Biochem J; 2005 Nov; 392(Pt 1):191-9. PubMed ID: 16053446
[TBL] [Abstract][Full Text] [Related]
28. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
Etemad-Moghadam B; Sun Y; Nicholson EK; Karlsson GB; Schenten D; Sodroski J
J Virol; 1999 Oct; 73(10):8873-9. PubMed ID: 10482646
[TBL] [Abstract][Full Text] [Related]
29. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
Cheng-Mayer C; Brown A; Harouse J; Luciw PA; Mayer AJ
J Virol; 1999 Jul; 73(7):5294-300. PubMed ID: 10364275
[TBL] [Abstract][Full Text] [Related]
30. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.
Parren PW; Wang M; Trkola A; Binley JM; Purtscher M; Katinger H; Moore JP; Burton DR
J Virol; 1998 Dec; 72(12):10270-4. PubMed ID: 9811774
[TBL] [Abstract][Full Text] [Related]
31. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression.
Shioda T; Oka S; Xin X; Liu H; Harukuni R; Kurotani A; Fukushima M; Hasan MK; Shiino T; Takebe Y; Iwamoto A; Nagai Y
J Virol; 1997 Jul; 71(7):4871-81. PubMed ID: 9188549
[TBL] [Abstract][Full Text] [Related]
32. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.
Zhang LQ; MacKenzie P; Cleland A; Holmes EC; Brown AJ; Simmonds P
J Virol; 1993 Jun; 67(6):3345-56. PubMed ID: 8497055
[TBL] [Abstract][Full Text] [Related]
33. Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences.
Smith AD; Resnick DA; Zhang A; Geisler SC; Arnold E; Arnold GF
J Virol; 1994 Jan; 68(1):575-9. PubMed ID: 8254775
[TBL] [Abstract][Full Text] [Related]
34. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
[TBL] [Abstract][Full Text] [Related]
35. Pathogen evolution within host individuals as a primary cause of senescence.
Bell G
Genetica; 1993; 91(1-3):21-34. PubMed ID: 8125270
[TBL] [Abstract][Full Text] [Related]
36. An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.
Vicenzi E; Dimitrov DS; Engelman A; Migone TS; Purcell DF; Leonard J; Englund G; Martin MA
J Virol; 1994 Dec; 68(12):7879-90. PubMed ID: 7966578
[TBL] [Abstract][Full Text] [Related]
37. A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus.
Shioda T; Oka S; Ida S; Nokihara K; Toriyoshi H; Mori S; Takebe Y; Kimura S; Shimada K; Nagai Y
J Virol; 1994 Dec; 68(12):7689-96. PubMed ID: 7966558
[TBL] [Abstract][Full Text] [Related]
38. Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.
Peifang S; Pira GL; Fenoglio D; Harris S; Costa MG; Venturino V; Dessì V; Layton G; Laman J; Huisman JG
Clin Exp Immunol; 1994 Sep; 97(3):361-6. PubMed ID: 7915974
[TBL] [Abstract][Full Text] [Related]
39. Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.
Resnick DA; Smith AD; Gesiler SC; Zhang A; Arnold E; Arnold GF
J Virol; 1995 Apr; 69(4):2406-11. PubMed ID: 7884887
[TBL] [Abstract][Full Text] [Related]
40. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
Muster T; Steindl F; Purtscher M; Trkola A; Klima A; Himmler G; Rüker F; Katinger H
J Virol; 1993 Nov; 67(11):6642-7. PubMed ID: 7692082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
